Bieffe Medical's first joint venture aims at China
This article was originally published in Clinica
Executive Summary
Bieffe Medital is entering the Chinese market in its first joint venture. The Italian manufacturer of parenteral solutions and medical devices is investing $8.4 million in a deal with Tianjin Amino Acid which will produce parenteral solutions in Tianjin. The facility's turnover should rise to some $10 million by the third year, predicts Bieffe's president Alberto Siccardi.